MedTrace Logo

SNAP 25 Gene Study

NCT00885560 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2012-09-18

No results posted yet for this study

Summary

To enhance our capacity to correctly choose the appropriate medication for ADHD patients on the first try based on the presence of a particular variant of a gene that could be identified on a laboratory test. It is hypothesized that patients with Attention Deficit Hyperactivity Disorder (ADHD) who have failed to respond to methylphenidate medication, but do respond to amphetamines, have a higher than expected incidence the allelic variants of the SNAP 25 gene associated with ADHD, and mutations of the dopamine system genes DRD1, 2, 4, 5 and dopamine transporter and COMTand MAOA.

Conditions

  • Attention-Deficit/Hyperactivity Disorder

Sponsors & Collaborators

  • UBC Human Early Learning Partnership (HELP)

    collaborator UNKNOWN

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Margaret D. Weiss, MD, Ph.D · University of British Columbia

  • Jim Kennedy, MD · University of British Columbia

  • Atilla Turgay, MD · British Columbia Children's & Women's Hospital

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00885560 on ClinicalTrials.gov